TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03726879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Study: NCT00913835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Olaratumab
Description: 20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: 20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
Study: NCT01827306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Study: NCT01629888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (3 test products/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (3 control products/day)
Study: NCT02431026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling pack activated Excel Cryo Cooling Collar
Description: Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
Study: NCT01505985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional Supplement
Description: Specialized nutritional supplement for seniors

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo product with no specific nutrients
Study: NCT03928015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive dronabinol
Description: 5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesics
Description: multimodal analgesia including opioid and non-opioid analgesics
Study: NCT03202173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 10% fluorescein
Description: The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 10% fluorescein
Description: The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 10% fluorescein
Description: The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
Study: NCT01737723

Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Monitoring stroke patients
Study: NCT03094377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory therapy
Description: Sensory stimulation, motor training and ADL training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Motor training and ADL training
Study: NCT03753269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: 2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: 15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
Study: NCT02706678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus sustained-release capsule
Description: Oral
Study: NCT04679363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
Study: NCT04408183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-1200
Description: GLS-1200 is given as a nasal spray using an atomizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given as a nasal spray using an atomizer
Study: NCT01555983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaporization of Cannabis
Description: Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaporization of Cannabis
Description: Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaporization of Cannabis
Description: Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
Study: NCT00914173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanlaf Circulator and water bath
Description: Cold Pressor Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc TSA 2000
Description: Thermal stimuli pain
Study: NCT00892242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT02611037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
Study: NCT00335153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study: NCT04638387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PB125
Description: Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to P125
Study: NCT01495780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Health Monitoring
Description: 1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
Study: NCT02849262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan (CLS001) topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical gel
Study: NCT03111095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
Study: NCT01238029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Capecitabine and Vinorelbine
Description: Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
Study: NCT04500743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin acetate
Description: Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
Study: NCT04344990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia - Group E
Description: Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral blockade - Group F
Description: Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular infusion - Group I
Description: Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
Study: NCT01648283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV racemic methadone HCl
Description: IV racemic Methadone HC1 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral racemic methadone HCl
Description: oral d5-methadone HCl 11 mg
Study: NCT00828620

Intervention type: OTHER
Intervention: Imaging study
Description: PET-CT
Study: NCT02899637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active high-frequency Transcranial Magnetic Stimulation
Description: Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham high-frequency Transcranial Magnetic Stimulation
Description: Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
Study: NCT03506490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: The training session lasted 45 minutes and was composed of running exercises.
Study: NCT02900404

Intervention type: OTHER
Intervention: XAPPORT
Description: A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
Study: NCT02611037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Cancer Symptom Scale for Mesothelioma Questionnaire
Description: Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
Study: NCT03487549

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 Cantharidin topical film forming solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 Cantharidin, topical film forming solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
Study: NCT01793831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT
Description: Standard FMT
Study: NCT02900404

Intervention type: OTHER
Intervention: XAPPORT
Description: A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.

Intervention type: OTHER
Intervention: Expert Panel (gold standard)
Description: A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.

Intervention type: OTHER
Intervention: Expert Panel (gold standard)
Description: A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
Study: NCT03366194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinStylus Sterilock System
Description: Microneedling device will be used to treat ventral hypertrophic scars.
Study: NCT03394833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gelofusine
Description: Preoperative colloid fluid bolus 6ml/kg ideal body weight
Study: NCT02585622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10\^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume total of fluid infused: 40 ml
Study: NCT03514017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
Study: NCT03471065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV
Description: Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
Study: NCT02452229

Intervention type: OTHER
Intervention: Review of the Literature for Human Herpes Virus infections
Description: Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used.
Study: NCT01112735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)
Description: Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study: NCT01997840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
Description: ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
Study: NCT02347917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: 480 mg orally twice daily (960 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
Study: NCT01051778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin 40mg plus low dose aspirin
Description: Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin calcium5,000 U twice daily plus low dose aspirin
Description: Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
Study: NCT02005666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
Description: Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUAC® Gel
Description: Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study: NCT03288350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mDCF + Avelumab
Description: Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
Study: NCT00927342

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivostat
Description: Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioGlue
Description: Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
Study: NCT04017884

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Remin Pro Forte
Description: a combination of chemicals with natural products cream .

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: a combination of chemicals